⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1802826 | 0.76 | — | — | |
| SCHEMBL6039758 | 0.76 | CHRM1 (0.34) | — | |
| Water SCHEMBL731137 | 0.76 | — | — | |
| SCHEMBL3861195 | 0.76 | — | — | |
| SCHEMBL1245328 | 0.76 | — | — | |
| SCHEMBL7746778 | 0.76 | — | — | |
| SCHEMBL3808280 | 0.76 | — | — | |
| SCHEMBL11727547 | 0.74 | CHRM1 (1.00) | — | |
| SCHEMBL7748527 | 0.74 | — | — | |
| SCHEMBL582879 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3921319-B1 | IMIDAZO [2, 1-F] [1, 2, 4] TRIAZIN-4-AMINE DERIVATIVES AS TLR7 AGONIST | BEIGENE LTD (KY) | 2024-03-06 | — | — | EP | claimed |
| EP-3921319-A1 | IMIDAZO [2, 1-F] [1, 2, 4] TRIAZIN-4-AMINE DERIVATIVES AS TLR7 AGONIST | BeiGene, Ltd. (KY) | 2021-12-15 | — | — | EP | claimed |
| CN-113423708-A | Imidazo [2,1-F ] [1,2,4] triazin-4-amine derivatives as TLR7 agonists | 百济神州有限公司 | 2021-09-21 | — | — | CN | claimed |
| WO-2020160710-A1 | IMIDAZO [2, 1-F] [1, 2, 4] TRIAZIN-4-AMINE DERIVATIVES AS TLR7 AGONIST | BEIGENE, LTD. (KY) | 2020-08-13 | — | — | WO | claimed |
| US-20110195898-A1 | TREATMENT OF ALZHEIMER'S DISEASE AND MILD COGNITIVE IMPAIRMENT USING GNRH-I ANALOGS AND ONE OR MORE OF ACETYLCHOLINESTERASE INHIBITORS AND NMDA RECEPTOR ANTAGONISTS | VOYAGER PHARMACEUTICAL CORPORATION (US) | 2011-08-11 | — | — | US | claimed |
| US-20080171736-A1 | Treatment of Alzheimer's Disease and Mild Cognitive impairment using GnRH-I analogs and one or more of acetylcholinesterase inhibitors and NMDA receptor antagonists | VOYAGER PHARMACEUTICAL CORPORATION | 2008-07-17 | — | — | US | claimed |
| EP-0683792-B1 | LHRH ANTAGONISTS HAVING MODIFIED AMINOACYL RESIDUES AT POSTIONS 5 AND 6 | ABBOTT LAB (US) | 2001-09-26 | — | — | EP | claimed |
| EP-0673254-A4 | 6-POSITION MODIFIED DECAPEPTIDE LHRH ANTAGONISTS. | ABBOTT LAB (US) | 1998-11-18 | — | — | EP | claimed |
| EP-0683792-A4 | LHRH ANTAGONISTS HAVING MODIFIED AMINOACYL RESIDUES AT POSTIONS 5 AND 6. | ABBOTT LAB (US) | 1998-11-18 | — | — | EP | claimed |
| US-5698522-A | INHIBIT RELEASE OF LUTEINIZING HORMONE RELEASING HORMONE | ABBOTT LABORATORIES (US) | 1997-12-16 | — | — | US | claimed |
| EP-0673254-A1 | 6-POSITION MODIFIED DECAPEPTIDE LHRH ANTAGONISTS | ABBOTT LABORATORIES (US) | 1995-09-27 | — | — | EP | claimed |
| WO-1994014841-A1 | LHRH ANTAGONISTS HAVING MODIFIED AMINOACYL RESIDUES AT POSTIONS 5 AND 6 | ABBOTT LABORATORIES (US) | 1994-07-07 | — | — | WO | claimed |
| WO-1994013313-A1 | 6-POSITION MODIFIED DECAPEPTIDE LHRH ANTAGONISTS | ABBOTT LABORATORIES (US) | 1994-06-23 | — | — | WO | claimed |
| US-5110904-A | Luteinizing hormone releasing hormone; suppression of sex hormones | ABBOTT LABORATORIES (US) | 1992-05-05 | — | — | US | claimed |
| EP-0400065-A4 | LHRH ANALOGS | — | 1991-03-13 | — | — | EP | claimed |
| EP-0413209-A1 | LHRH analogs | TAP Pharmaceuticals Inc. (US) | 1991-02-20 | — | — | EP | claimed |
| EP-0400065-A1 | LHRH ANALOGS. | ABBOTT LAB (US) | 1990-12-05 | — | — | EP | claimed |
| WO-1989007450-A1 | LHRH ANALOGS | ABBOTT LABORATORIES (US) | 1989-08-24 | — | — | WO | claimed |
| EP-0328090-A2 | LHRH analogs | ABBOTT LABORATORIES (US) | 1989-08-16 | — | — | EP | claimed |
| EP-0151319-B1 | Hexahydrobenzo[de]quinoline derivatives and their preparation | ELI LILLY AND COMPANY (US) | 1988-04-20 | — | — | EP | claimed |